Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.39 |
| ▸ | GSR | P00390 | 2/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191236 | 1.00 | NOS3 (0.41) | NOS3NOS1NOS2ALDH1A1SLC1A2 | |
| SCHEMBL490891 | 1.00 | NOS3 (0.41) | NOS3NOS1NOS2ALDH1A1SLC1A2 | |
| SCHEMBL28580283 | 0.90 | GSR (0.43) | NOS3NOS1NOS2ALDH1A1GSR | |
| SCHEMBL13639864 | 0.84 | SLC1A1 (0.55) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL19699429 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL1067509 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL1067514 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL30980082 | 0.83 | IDO1 (0.34) | SLC1A1 | |
| SCHEMBL10314812 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2ALDH1A1SLC1A2 | |
| SCHEMBL20591675 | 0.81 | NOS3 (0.38) | NOS3NOS1NOS2ALDH1A1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210329924-A1 | METAL-BASED ANTIMICROBIAL COMPOSITION AND METHOD OF USING | APEX BIOMATERIALS INC. (CA) | 2021-10-28 | — | — | US | claimed |
| US-20190177169-A1 | MODIFIED GRAPHITE INTERCALATED COMPOUNDS AND METHODS OF MAKING AND USING THEM | MEGAMATTER, INC. (US) | 2019-06-13 | — | — | US | claimed |
| EP-3468914-A1 | MODIFIED GRAPHITE INTERCALATED COMPOUNDS AND METHODS OF MAKING AND USING THEM | Megamatter Inc. (US) | 2019-04-17 | — | — | EP | claimed |
| WO-2017218547-A1 | MODIFIED GRAPHITE INTERCALATED COMPOUNDS AND METHODS OF MAKING AND USING THEM | MEGAMATTER, INC. (US) | 2017-12-21 | — | — | WO | claimed |
| US-8998518-B2 | Dual cleaning apparatus | MUHR-SWEENEY AUDREY (US) | 2015-04-07 | — | — | US | claimed |
| US-20140110263-A1 | Superhydrophobic Anodized Metals and Method of Making Same | U.S. DEPARTMENT OF ENERGY | 2014-04-24 | — | — | US | claimed |
| US-20130327357-A1 | DUAL CLEANING APPARATUS | MUHR-SWEENEY AUDREY (US) | 2013-12-12 | — | — | US | claimed |
| US-8534945-B2 | Dual cleaning apparatus | MUHR-SWEENEY AUDREY (US) | 2013-09-17 | — | — | US | claimed |
| US-20120207530-A1 | DUAL CLEANING APPARATUS | MUHR-SWEENEY AUDREY (US) | 2012-08-16 | — | — | US | claimed |
| US-7553100-B2 | Dual cleaning apparatus | MUHR-SWEENEY AUDREY | 2009-06-30 | — | — | US | claimed |
| US-20050147455-A1 | Dual cleaning apparatus | MUHR-SWEENEY AUDREY (US) | 2005-07-07 | — | — | US | claimed |
| US-20040136770-A1 | Dual cleaning apparatus | MUHR-SWEENEY AUDREY (US) | 2004-07-15 | — | — | US | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3570864-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4423014-B1 | OPTIMIZED METHOD FOR THE PREPARATION AND ISOLATION OF HYDROCYANIC ACID AND METHOD FOR ITS CONVERSION TO METHACRYLIC ACID (MAS) AND / OR ALKYL METHACRYLATE | ROEHM GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| EP-0322796-A1 | Production method of hydrocyanic acid | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0108737-B1 | HYDROGEN CYANIDE PROCESS | Monsanto Company (US) | 1986-05-21 | — | — | EP | disclosed |
| US-4457904-A | Hydrogen cyanide process | MONSANTO COMPANY (US) | 1984-07-03 | — | — | US | disclosed |
| EP-0108737-A1 | Hydrogen cyanide process | Monsanto Company (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | NOS3 810/4885NOS1 1575/4885NOS2 1919/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | NOS3 881/4885NOS1 2111/4885NOS2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.